BioSpecifics seeks to partner with companies that possess novel therapeutics that will deliver meaningful benefits for patients. BioSpecifics contemplates entering into a range of creative transactions that mutually benefit potential partners in their efforts to progress their scientific and business objectives.

BioSpecifics is currently partnered with Endo for CCH (marketed in the U.S. under the trade name XIAFLEX®) and Endo continues to manage the research and development of XIAFLEX® and CCH for their licensed indications.

For further inquiries, please reach out to